Benzinga | Sep 15, 2021 06:08AM EDT

HC Wainwright & Co. Maintains Buy on Redhill Biopharma, Lowers Price Target to $21

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Redhill Biopharma (NASDAQ:RDHL) with a Buy and lowers the price target from $23 to $21.